Genentech files sBLA for Lucentis for diabetic retinopathy
Genentech, the biotech subsidiary of Swiss pharma major Roche (ROG: SIX), has submitted a supplemental Biologics License Application (sBLA) with the US Food and Drug Administrationfor Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR).
DR is the most common diabetic eye disease and leading cause of new cases of blindness in working-age Americans, impacting nearly 7.7 million Americans. With no ocular medications currently approved for DR, this is the first of its kind submission, further demonstrating Genentech’s leadership and commitment to ophthalmology, the company stated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze